PegBio Signs Material Transfer Agreement with SN BioScience

MT Newswires Live

Sep 02

PegBio (HKG:2565) entered into a material transfer agreement with SN BioScience, according to a Wednesday Hong Kong bourse filing.

Under the agreement, the parties will combine SN BioScience's proprietary Serinol Nucleic Acids long-acting drug delivery platform with three innovative peptide drug candidates for metabolic diseases developed by PegBio.

The parties will research formulation and long-acting delivery to evaluate the in vivo performance, pharmacokinetic characteristics and further development potential of the candidate-platform combinations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/news/2664158578"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664158578\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664158578?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 18:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664158578","market":"nz","top_or_hot":-1,"title":"PegBio Signs Material Transfer Agreement with SN BioScience","media":"MT Newswires Live","content":"<html><body><p> PegBio (HKG:2565) entered into a material transfer agreement with SN BioScience, according to a Wednesday Hong Kong bourse filing.</p><p>Under the agreement, the parties will combine SN BioScience's proprietary Serinol Nucleic Acids long-acting drug delivery platform with three innovative peptide drug candidates for metabolic diseases developed by PegBio.</p><p>The parties will research formulation and long-acting delivery to evaluate the in vivo performance, pharmacokinetic characteristics and further development potential of the candidate-platform combinations.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PegBio Signs Material Transfer Agreement with SN BioScience</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPegBio Signs Material Transfer Agreement with SN BioScience\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-02 18:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PegBio (HKG:2565) entered into a material transfer agreement with SN BioScience, according to a Wednesday Hong Kong bourse filing.</p><p>Under the agreement, the parties will combine SN BioScience's proprietary Serinol Nucleic Acids long-acting drug delivery platform with three innovative peptide drug candidates for metabolic diseases developed by PegBio.</p><p>The parties will research formulation and long-acting delivery to evaluate the in vivo performance, pharmacokinetic characteristics and further development potential of the candidate-platform combinations.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SN","symbol_name":"SHARKNINJA INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664158578","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664158578","pubTimestamp":1788346064,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PegBio  entered into a material transfer agreement with SN BioScience, according to a Wednesday Hong Kong bourse filing.Under the agreement, the parties will combine SN BioScience's proprietary Serinol Nucleic Acids long-acting drug delivery platform with three innovative peptide drug candidates for metabolic diseases developed by PegBio.The parties will research formulation and long-acting delivery to evaluate the in vivo performance, pharmacokinetic characteristics and further development potential of the candidate-platform combinations.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SN":"SHARKNINJA INC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4191":"家用电器","02565":"派格生物医药-B","BK1161":"生物科技","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD"},"translate_title":"PegBio 与 SN BioScience 签署材料转让协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1,"SN":1.5},"content_text":"PegBio (HKG:2565) entered into a material transfer agreement with SN BioScience, according to a Wednesday Hong Kong bourse filing.Under the agreement, the parties will combine SN BioScience's proprietary Serinol Nucleic Acids long-acting drug delivery platform with three innovative peptide drug candidates for metabolic diseases developed by PegBio.The parties will research formulation and long-acting delivery to evaluate the in vivo performance, pharmacokinetic characteristics and further development potential of the candidate-platform combinations.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}